['\xe2\x86\x91\xc2\xa0\xc2\xa0INDICATES INCREASE.', '\xe2\x86\x93\xc2\xa0\xc2\xa0INDICATES DECREASE.', 'A ONLY IF OTHER DRUGS ARE NOT AVAILABLE AND IF CLEARLY INDICATED. IF TREATMENT WITH LIFE-SUSTAINING DRUGS THAT CAUSE PANCREATIC TOXICITY IS REQUIRED, SUSPENSION OF VIDEX IS RECOMMENDED [ SEE WARNINGS AND PRECAUTIONS (5.1) ].', 'B [ SEE WARNINGS AND PRECAUTIONS (5.6) .]', 'DRUGS THAT MAY CAUSE PANCREATIC TOXICITY', '\xe2\x86\x91\xc2\xa0RISK OF PANCREATITIS', 'USE ONLY WITH EXTREME CAUTION A', 'NEUROTOXIC DRUGS', '\xe2\x86\x91\xc2\xa0RISK OF NEUROPATHY', 'USE WITH CAUTION B', 'ANTACIDS CONTAINING MAGNESIUM OR ALUMINUM', '\xe2\x86\x91\xc2\xa0SIDE EFFECTS ASSOCIATED WITH ANTACID COMPONENTS', 'USE CAUTION WITH VIDEX PEDIATRIC POWDER FOR ORAL SOLUTION', 'AZOLE ANTIFUNGALS', '\xe2\x86\x93\xc2\xa0KETOCONAZOLE OR ITRACONAZOLE CONCENTRATION', 'ADMINISTER DRUGS SUCH AS KETOCONAZOLE OR ITRACONAZOLE AT LEAST 2\xc2\xa0HOURS BEFORE VIDEX.', 'QUINOLONE ANTIBIOTICS (SEE ALSO CIPROFLOXACIN IN TABLE 8 )', '\xe2\x86\x93\xc2\xa0QUINOLONE CONCENTRATION', 'CONSULT PACKAGE INSERT OF THE QUINOLONE.', 'TETRACYCLINE ANTIBIOTICS', '\xe2\x86\x93\xc2\xa0ANTIBIOTIC CONCENTRATION', 'CONSULT PACKAGE INSERT OF THE TETRACYCLINE.']